









Markets
/
Stocks
/
nasdaq-adtx
/

Aditxt Inc

ADTX

0.970USD

-0.040-3.96%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.08MMarket Cap

LossP/E TTM



Aditxt Inc

0.970

-0.040-3.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

295 / 506

Overall Ranking

519 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Growing

The company is in a growing phase, with the latest annual income totaling USD 133.99K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.75.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.06, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.00K, representing a year-over-year decrease of 97.73%, while its net profit experienced a year-over-year decrease of 3.88%.

Score

Industry at a Glance

Previous score

5.06

Change



Financials

3.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.95

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 7.29, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.00, which is -Inf% below the recent high of -0.03 and +Inf% above the recent low of -0.07.

Score

Industry at a Glance

Previous score

7.29

Change

0.03

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 295/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.00, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.13 and the support level at 0.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.00

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Neutral

RSI(14)

43.979

Neutral

STOCH(KDJ)(9,3,3)

41.091

Sell

ATR(14)

0.071

High Vlolatility

CCI(14)

-38.305

Neutral

Williams %R

63.810

Sell

TRIX(12,20)

-0.299

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.004

Sell

MA10

1.008

Sell

MA20

1.014

Sell

MA50

1.079

Sell

MA100

1.332

Sell

MA200

15.039

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

0.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

No Data

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.91, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.